Wells Fargo & Company Krystal Biotech, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 16,928 shares of KRYS stock, worth $3.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,928

Previous 13,956 21.3%

Holding current value

$3.07 Million

Previous $2.54 Million 4.49%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$156.64 - $199.61 $465,534 - $593,240	2,972 Added 21.3%	16,928 $2.65 Million
Q3 2024 Nov 13, 2024	SELL	$174.7 - $213.66 $93,289 - $114,094	-534 Reduced 3.69%	13,956 $2.54 Million
Q2 2024 Aug 13, 2024	BUY	$153.12 - $183.64 $816,435 - $979,168	5,332 Added 58.22%	14,490 $2.66 Million
Q1 2024 May 10, 2024	BUY	$108.01 - $179.35 $172,599 - $286,601	1,598 Added 21.14%	9,158 $1.63 Million
Q4 2023 Feb 09, 2024	SELL	$96.0 - $128.29 $1.19 Million - $1.6 Million	-12,433 Reduced 62.19%	7,560 $937,000
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $186,637 - $223,978	-1,720 Reduced 7.92%	19,993 $2.32 Million
Q2 2023 Aug 15, 2023	BUY	$78.48 - $130.32 $276,877 - $459,768	3,528 Added 19.4%	21,713 $2.55 Million
Q1 2023 May 12, 2023	BUY	$72.39 - $84.27 $1.01 Million - $1.17 Million	13,915 Added 325.88%	18,185 $1.46 Million
Q4 2022 Feb 13, 2023	SELL	$63.14 - $79.9 $40,851 - $51,695	-647 Reduced 13.16%	4,270 $338,000
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $25,032 - $31,806	-386 Reduced 7.28%	4,917 $343,000
Q2 2022 Aug 12, 2022	SELL	$48.93 - $73.47 $211,230 - $317,169	-4,317 Reduced 44.88%	5,303 $348,000
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $277,886 - $385,427	-5,345 Reduced 35.72%	9,620 $640,000
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $369,755 - $819,573	9,288 Added 163.61%	14,965 $1.05 Million
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $284,598 - $392,725	5,472 Added 2669.27%	5,677 $296,000
Q2 2021 Aug 16, 2021	SELL	$62.14 - $81.82 $92,526 - $121,829	-1,489 Reduced 87.9%	205 $14,000
Q1 2021 May 13, 2021	SELL	$59.42 - $85.46 $729,677 - $1.05 Million	-12,280 Reduced 87.88%	1,694 $130,000
Q4 2020 Feb 09, 2021	SELL	$40.64 - $61.38 $460,735 - $695,865	-11,337 Reduced 44.79%	13,974 $839,000
Q3 2020 Nov 05, 2020	SELL	$37.76 - $48.49 $6.62 Million - $8.5 Million	-175,211 Reduced 87.38%	25,311 $1.09 Million
Q2 2020 Aug 13, 2020	BUY	$37.03 - $60.0 $2.52 Million - $4.09 Million	68,105 Added 51.43%	200,522 $8.31 Million
Q1 2020 May 14, 2020	BUY	$35.02 - $65.64 $4.64 Million - $8.69 Million	132,417 New	132,417 $5.73 Million

Others Institutions Holding KRYS

# of Institutions

299

Shares Held

24.3M

Call Options Held

388K

Put Options Held

233K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.65B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Krystal Biotech, Inc. Transaction History